Literature DB >> 12773498

Experimental autoimmune autonomic neuropathy.

Steven Vernino1, Phillip A Low, Vanda A Lennon.   

Abstract

Antibodies specific for the neuronal ganglionic nicotinic acetylcholine receptor (nAChR) are found in high titer in serum of patients with subacute autonomic failure. This clinical disorder is known as autoimmune autonomic neuropathy (AAN). Rabbits immunized with a neuronal nAChR alpha3 subunit fusion protein produce ganglionic nAChR antibodies and develop autonomic failure (experimental AAN, or EAAN). We used quantitative measures of autonomic function to demonstrate that this animal model of neuronal nAChR autoimmunity recapitulates the cardinal autonomic features of AAN in humans. The severity of dysautonomia in the rabbit ranges from isolated cardiovagal impairment to severe panautonomic failure with fixed mydriasis, gastroparesis, dry eyes, impaired heart rate variability, hypotension, and low plasma catecholamines. The severity of autonomic failure correlates with serum antibody levels. Immunohistochemical staining of superior cervical ganglia and myenteric plexus neurons demonstrates intact presynaptic nerve terminals and intact postsynaptic neurons containing cytoplasmic nAChR, but lacking surface nAChR. These findings define the autonomic physiology and histopathology of this novel animal model and support the concept that AAN in humans is a disorder of ganglionic cholinergic synaptic transmission caused by ganglionic nAChR antibodies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12773498     DOI: 10.1152/jn.00408.2003

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  22 in total

Review 1.  Other autonomic neuropathies associated with ganglionic antibody.

Authors:  Paola Sandroni; Phillip A Low
Journal:  Auton Neurosci       Date:  2008-12-04       Impact factor: 3.145

2.  Characterization of ganglionic acetylcholine receptor autoantibodies.

Authors:  Steven Vernino; Jon Lindstrom; Steve Hopkins; Zhengbei Wang; Phillip A Low
Journal:  J Neuroimmunol       Date:  2008-05-15       Impact factor: 3.478

3.  The spectrum of clinicopathological features in pure autonomic neuropathy.

Authors:  Haruki Koike; Rina Hashimoto; Minoru Tomita; Yuichi Kawagashira; Masahiro Iijima; Shigeru Koyano; Takayuki Momoo; Hiroyuki Yuasa; Shigehisa Mitake; Mana Higashihara; Kenichi Kaida; Daisuke Yamamoto; Shin Hisahara; Shun Shimohama; Yoshiharu Nakae; Ken Johkura; Steven Vernino; Gen Sobue
Journal:  J Neurol       Date:  2012-02-24       Impact factor: 4.849

Review 4.  Paraneoplastic syndromes: an approach to diagnosis and treatment.

Authors:  Lorraine C Pelosof; David E Gerber
Journal:  Mayo Clin Proc       Date:  2010-09       Impact factor: 7.616

5.  Sudomotor dysfunction in autoimmune autonomic ganglionopathy: a follow-up study.

Authors:  Kurt Kimpinski; Valeria Iodice; Paola Sandroni; Robert D Fealey; Steven Vernino; Phillip A Low
Journal:  Clin Auton Res       Date:  2011-11-30       Impact factor: 4.435

Review 6.  Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy.

Authors:  Steven Vernino; Steve Hopkins; Zhengbei Wang
Journal:  Auton Neurosci       Date:  2008-10-31       Impact factor: 3.145

7.  Sudomotor dysfunction in autoimmune autonomic ganglionopathy.

Authors:  K Kimpinski; V Iodice; P Sandroni; R D Fealey; S Vernino; P A Low
Journal:  Neurology       Date:  2009-11-03       Impact factor: 9.910

Review 8.  Invited Article: Autonomic ganglia: target and novel therapeutic tool.

Authors:  Steven Vernino; Paola Sandroni; Wolfgang Singer; Phillip A Low
Journal:  Neurology       Date:  2008-05-13       Impact factor: 9.910

Review 9.  Autoimmune and paraneoplastic channelopathies.

Authors:  Steven Vernino
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

Review 10.  Neurogenic orthostatic hypotension: a pathophysiological approach.

Authors:  David S Goldstein; Yehonatan Sharabi
Journal:  Circulation       Date:  2009-01-06       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.